Sheffield United moved back to the top of the Championship table despite being denied a win by a last-minute Bristol City ...
Bristol Myers Squibb buys 2seventy bio for $286 million, strengthening its cancer portfolio with Abecma CAR-T therapy for ...
The deal ends 2Seventy’s short run as an independent company, during which it restructured, sold off research and lost nearly ...
Abecma made $406 million in 2024, of which BMS paid $43 million to 2seventy bio as part of their profit-sharing agreement.